Last updated on November 2019

Study of the Safety Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma


Brief description of study

The purpose of this study is to establish the safety, tolerability, pharmacokinetics and RP2D (Recommended Phase II Dose) of orally administered HZ-A-018 in patients with B cell lymphoma who have at least failed or relapsed after first-line treatment.

Clinical Study Identifier: NCT04173455

Find a site near you

Start Over